

Now Enrolling

Encore-MDS Study: A Clinical Trial in Lower-risk Myelodysplastic Syndrome

A clinical study to evaluate the safety and efficacy of RVT-2001, an **oral investigational medication**, in patients with **lower-risk MDS who are transfusion dependent**.

Select Eligibility Criteria



Lower-Risk MDS



Red Blood Cell Transfusion Dependent



Carry a SF3B1 Mutation

If you or a loved one have been diagnosed with MDS and are interested in participating, fill out the questionnaire at EncoreMDS.com.

- No prior lenalidomide or hypomethylating agent such as azacytidine or decitabine
- Failed or refractory to erythropoiesis stimulating agents
- Be at least 18 years old

Hemavant Patient Center
(213) 549-2979
hemavant@patientwing.com

RVT-2001 is an investigational drug that has not been approved by the FDA or any other regulatory health authority. Safety and efficacy have not been established.



Study Design: Dose-optimization

Patient may continue treatment until disease progression

